WARREN, N.J. and ROYAL OAK, Mich., February 26, 2026
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has signed a non-exclusive, non-binding Letter of Intent (LoI) to evaluate the potential acquisition of Sciometrix Inc., a healthcare technology company and developer of the Clínicus digital care management platform. If consummated, the transaction would result in Tevogen holding a majority voting interest in Sciometrix, marking a strategic move to integrate digital health infrastructure with its cell therapy pipeline and AI-driven drug development platform. The proposed acquisition reflects Tevogen’s ambition to evolve into a revenue-generating healthcare enterprise while strengthening its commercialization and clinical operations capabilities.
Integrating Digital Care with Biotech Innovation
Tevogen is evaluating the integration of Sciometrix’s Clínicus platform and remote patient monitoring technologies into its proprietary Tevogen.AI initiative, aiming to enhance clinical development, patient engagement, and data-driven decision-making. The company believes the acquisition could accelerate commercialization readiness by combining therapeutic innovation with real-world outcomes tracking and predictive analytics. By embedding enterprise care management tools into its operational framework, Tevogen intends to support value-based healthcare models, align treatment delivery with reimbursement requirements, and reduce barriers between innovation and patient access. This biotech-plus-services approach could differentiate Tevogen in a competitive life sciences environment increasingly shaped by digital transformation and health data integration.
Strengthening AI-Driven Clinical Development
Tevogen’s broader strategy centers on leveraging artificial intelligence and precision T cell therapy platforms, including its proprietary ExacTcell™ technology, to accelerate therapeutic discovery and optimize clinical trial design. The potential acquisition of Sciometrix would enhance Tevogen’s data capabilities through Clinicus’ predictive analytics infrastructure, supporting improved trial efficiency, patient monitoring, and longitudinal outcomes reporting. By integrating digital care management with advanced immunotherapy programs, Tevogen aims to build an ecosystem that connects drug development, clinical operations, and patient-centric engagement within a unified framework. Company leadership emphasized that strategic acquisitions are intended not only to add revenue but to build scalable infrastructure that can support long-term innovation across oncology, virology, and neurology programs.
Advertisement
Transaction Subject to Due Diligence
The proposed transaction remains subject to completion of due diligence, negotiation of definitive agreements, regulatory approvals, and customary closing conditions. As a non-binding LoI, there can be no assurance the acquisition will be finalized. Nonetheless, the announcement signals Tevogen’s active pursuit of life sciences–related strategic transactions to strengthen its competitive positioning and operational capabilities. In a market where biotechnology companies increasingly seek to integrate AI analytics, real-world evidence generation, and digital patient management systems, Tevogen’s initiative reflects a broader industry shift toward convergence between therapeutic development and healthcare technology platforms.
If completed, the acquisition could mark a structural transformation for Tevogen, aligning its immunotherapy and AI assets with scalable digital health infrastructure to create a differentiated, integrated healthcare enterprise capable of navigating regulatory complexity, reimbursement dynamics, and global commercialization challenges.
Source: Tevogen press release
